Moderate

Subclinical hyperthyroidism

subclinical · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Low or suppressed TSH with normal free T4 and T3, most often from toxic nodular disease, Graves or excess thyroxine. Management depends on degree of TSH suppression, age and cardiac/bone risk.

Red flags

  • New atrial fibrillation or heart failure
  • Osteoporotic fragility fracture
  • Progression to overt thyrotoxicosis
  • Marked symptoms in the elderly

Assessment

Differential diagnosis

  • Overt hyperthyroidism (if free hormones rise)
  • Non-thyroidal illness (recovery phase)
  • Pituitary/hypothalamic disease
  • Drug effect (steroids, dopamine)
  • Exogenous levothyroxine over-replacement

Investigations

  • Repeat TSH, free T4 and free T3 after 2-3 months to confirm persistence
  • TSH-receptor antibodies
  • Thyroid uptake scan or ultrasound for nodular vs diffuse cause
  • ECG for atrial fibrillation
  • Bone density assessment in postmenopausal women

Management

  • Confirm persistence on repeat testing before acting
  • Grade severity: TSH 0.1-0.4 (grade 1) vs TSH <0.1 mU/L (grade 2)
  • Identify the cause (nodular, Graves, exogenous)
  • Reduce or adjust levothyroxine dose if over-replacement is the cause
  • Treat grade 2 suppression, especially with age >=65, atrial fibrillation, osteoporosis or cardiac disease
  • Use antithyroid drugs or definitive therapy (radioiodine/surgery) for persistent endogenous disease
  • Observe younger, low-risk patients with periodic monitoring
  • Manage cardiovascular and bone risk
  • Re-evaluate thyroid status regularly

Drugs & doses

Carbimazole 5-20 mg PO once daily titrated to response
Propylthiouracil 50-150 mg PO daily as alternative
Beta-blocker (e.g. propranolol 10-40 mg PO as needed) for symptoms/AF rate
Adjusted levothyroxine dose if iatrogenic

Disposition

Monitor low-risk patients in primary care; refer to endocrinology for grade 2 suppression, high-risk features or definitive therapy planning.

Complications & pitfalls

  • Atrial fibrillation and thromboembolism
  • Accelerated bone loss and fractures
  • Progression to overt hyperthyroidism
  • Cardiovascular mortality (persistent grade 2)

Exam pearls

  • A single low TSH does not warrant treatment; confirm persistence first
  • TSH <0.1 mU/L in those over 65 or with cardiac/bone disease is the clearest treatment indication
  • Over-replacement with levothyroxine is a common, easily reversible cause
  • Suppressed TSH independently raises atrial fibrillation and fracture risk

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.